BioSpace News Archive

Chance Pharmaceuticals, a clinical-stage biotechnology company focusing on discovering, developing, and commercializing inhalation therapies for debilitating diseases, announced the completion of a Series C+ financing led exclusively by new investor Fortune Venture Capital.

BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it has been awarded a Small Business Technology Transfer Phase I grant for $256,000.

A research team led by Professor Gong Chen of Jinan University, also the scientific founder of NeuExcell Therapeutics Group, published an article in the latest issue of Progress in Neurobiology, using neuroregenerative gene therapy to treat temporal lobe epilepsy in rats.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Frank McCormick, Ph.D., FRS, to Chair of the IDEAYA Scientific Advisory Board.

CB Scientific, Inc. announced that the company will convene a Special Meeting of Stockholders on Friday, January 14, 2022, at 10:00 a.m. Eastern Standard Time.

eureKARE is pleased to announce that it has participated in DNA Script’s $200 million Series C financing which today closed with completion of the second tranche.

Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. (ET).

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 am ET.

Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform.

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman, will present at the 40th Annual J.P. Morgan Healthcare Conference.